Alcohol Drinking
result Completed; results not posted
RCTNCT002270582005 · n=100 · University of Mississippi Medical Center Seasonal Allergic Rhinitis
tested Improvement in nasal symptom scores from baseline after intervention
result Completed; results not posted
RCTNCT00266331Phase 2 · 2004 · n=150 · Nathalie Johnson Breast Cancer
tested Reduction in skin damage
result Completed; results not posted
RCTNCT00506688Phase 2 · 2007 · n=153 · Mukoviszidose Institut gGmbH Cystic Fibrosis
tested Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)
result Completed; results not posted
Autism
tested Improvement in both developmental skills and behavior with either glutathione or glutathione, Vitamin C and N-acetylcysteine therapy as compared to placebo therapy. Subjects will also be monitored using clinical and laboratory safety parameters.
result Completed; results not posted
Small sample; effect at the edge of clinical significance.
RCTNCT010442772010 · n=61 · Milton S. Hershey Medical Center Healthy Adults
tested Evaluation of the effect of glutathione on key biomarkers
result Completed; results not posted
RCTNCT01450267Phase 3 · 2010 · n=150 · Serafino A. Marsico Cystic Fibrosis
tested Forced expiratory volume in one second (FEV1) percent
result In progress (unknown)
RCTNCT02251041Phase 2 · 2014 · n=143 · Universitaire Ziekenhuizen KU Leuven Reperfusion Injury
tested Peak Aspartate Aminotransferase Within First 72h Post Transplant
result −188 U/L (Peak Aspartate Aminotransferase Within First 72h P…)
RCTNCT02311907Phase 3 · 2009 · n=195 · Alliance for Clinical Trials in Oncology Chemotherapeutic Agent Toxicity
tested Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).
result +1.6 Units on a scale 1-100 (Paclitaxel/Carboplatin (PC) Induced Peripheral Neu…)
RCTNCT02848417Phase 1 · 2016 · n=75 · South Florida Veterans Affairs Foundation for Research and Education Gulf War Syndrome
tested Biomarker response to therapy using a VO2 exercise test
result In progress (unknown)
RCTNCT03020719Phase 2 · 2017 · n=60 · University of Minnesota Cystic Fibrosis
tested Change in Weight-for-age Z-score
result −0.1 Z-score (Change in Weight-for-age Z-score)
RCTNCT04105504Phase 1 · 2018 · n=90 · Dr Irma Bernadette S Sitohang Glutathione
tested Change from Baseline Spot UV at 4 weeks
result Completed; results not posted
RCTNCT06620523Phase 2 · 2024 · n=242 · George Washington University Renal Failure
tested AKI incidence reduction
result In progress (recruiting)
RCTNCT06896422Phase 1 · 2025 · n=80 · The First Affiliated Hospital of Zhengzhou University Non-Small Cell Lung Cancer
tested Progression-Free Survival (PFS)
result In progress (recruiting)
RCTNCT07572890Phase 1 · 2026 · n=100 · Adia Med of Winter Park LLC Chronic Kidney Disease
tested Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
result In progress (recruiting)
Gingival Pigmentation
tested Degree of gingival pigmentation by Takashi index (Hanioka et al., 2005)
result In progress (recruiting)
RCTNCT07622316Phase 1 · 2026 · n=100 · Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder
tested Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6
result In progress (recruiting)
Treatment studies
tested weight-for-age z score, BMI z score, height z score, fecal calprotectin, liver function, systemic inflammation
result GSH gained +0.67 SD wfaszs (19.1 percentile pts) vs +0.1 SD (2.1 pts) placebo; BMI +0.69 SD vs +0.22 SD; height +0.2 SD vs -0.06 SD; fecal calprotectin -52.0 vs +0.5; all P<0.0001
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested skin lightening (spectrophotometry) and facial dark spot size/color at 6 and 12 weeks
result Significant skin lightening and reduction in facial dark spot size after 12 weeks with L-Cystine 500 mg + L-Glutathione 250 mg combo; superior to placebo, L-Cystine alone, and GSH alone.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Ultrasound liver steatosis grade, Hepatic Steatosis Index (HSI)
result Nutraceutical group (Vit E + L-glutathione + silymarin) showed greater NAFLD regression; HSI improved 49.3±10.1 → 43.3±9.0 (p=0.01) vs diet alone.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested liver function (ALT, AST, TBIL, ALB), fibrosis markers (HA, PC III, LN), HBV-DNA negative conversion rates, adverse reactions
result ALT: 348.96→31.11 U/L (GSH+ETV) vs 347.90→56.90 U/L (ETV alone). Fibrosis markers and HBV-DNA clearance improved; no increase in adverse reactions.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested serum PCIII, IVC, TNF-a, IL-6, liver function markers, nutritional status
result Entecavir + glutathione group B achieved 97.82% effective treatment rate vs 76.08% in group A; greater reductions in TNF-a, IL-6, PCIII, IVC, ALT, AST, TBIL and improved nutritional parameters.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GSH/GSSG ratio in arterial cord blood, venous cord blood, and postnatal samples
result No significant difference in GSH/GSSG ratios: arterial cord 7.5 vs 37 (p=0.52), venous cord 8.4 vs 76 (p=0.12), postnatal 14 vs 8 (p=0.98).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
OpenNCT00323583Phase 2 · 2006 · n=80 · Seattle Cancer Treatment and Wellness Center Adenocarincoma of Pancreas
tested Clinical response rate (PS improvement by ECOG score, analgesic dose reduction)
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT02324426Phase 1 · 2014 · n=15 · University of Washington Parkinson's Disease
tested The concentration of metabolites before and after (in)GSH will be compared (change in mean GSH concentration)
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
OpenNCT05954052Phase 4 · 2019 · n=6 · University of Chicago Autism Spectrum Disorder
tested Aberrant Child Checklist, Looking at Change in the Subscale of the ABC
result Terminated before completion
Terminated: lack of funding and difficulty with phlebotomy in children with Autism
Treatment studies
tested HCV-RNA levels, liver enzymes (ALT), liver histology (HAI score), quality of life (SF-36)
result 48% favorable response in ≥1 parameter; ALT normalization in 44%; viral load decrease ≥1 log in 25%; histologic improvement in 36.1%; SF-36 improved in 58%. Well tolerated, no major AEs.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested platelet TBARS levels and platelet membrane fluidity (fluorescence polarization)
result TBARS decreased significantly (P=0.01); platelet membrane fluidity improved significantly (P=0.001) after 3 months antioxidant supplementation including L-glutathione 5 mg/day.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested flow-mediated dilation (RHI), arterial stiffness, lipid profile, oxidative stress markers
result LDL and total cholesterol reduced vs placebo (P=0.023, P=0.04); no difference in RHI or oxidative stress overall; n=7 with abnormal baseline RHI showed reduced arterial stiffness (P=0.007, P=0.037).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested pungency intensity of allyl isothiocyanate (AITC) and piperine via sensory evaluation
result GSH and γ-Glu-Val-Gly significantly increased AITC pungency; γ-Glu-Val-Gly also increased piperine pungency. GSH effect suppressed by CaSR inhibitor NPS-2143; anserine (no CaSR) had no effect.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested serum MDA, protein carbonyl, GSH, and total antioxidant capacity (TAC)
result Amlodipine vs placebo: MDA Hedges's g -0.59 (8.3% change difference), TAC g 0.42 (12.9%), GSH g 0.26 (3.1%), protein CO g -0.11 (2.2%); MDA and TAC met 5% clinical significance threshold.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested sperm DNA fragmentation index, concentration, total count, vitality
result DFI decreased 45.6%→34.8%; concentration 29.7→35.7×10⁶/mL; total count improved (p=0.012); vitality 75.5→81.1% (p<0.001)
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Association of ROS, GSH, and D-dimer levels at admission with mortality
result Non-survivors had high D-dimer and ROS; overall mortality 43% (30.6% moderate, 69.4% severe). Elevated ROS+D-dimer predicted poor outcomes; GSH direction not explicitly quantified.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Intracellular GSH/GSSG ratio and extracellular native thiol/disulphide balance in blood
result AD patients had lower GSH (p<0.001) and higher GSSG/GSH vs controls; GSSG/GSH predicted severity (OR 1.352 moderate, 1.829 severe); MMSE correlated rho=-0.488 with GSSG/GSH.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested incidence of acute kidney injury (AKI) per KDIGO/creatinine criteria
result AKI incidence 10.6% (GSH group) vs 18.0% (non-GSH group), p=0.009; multivariate OR=0.573 (95% CI 0.353–0.931, p=0.025) for GSH as independent protective factor.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested serum TNF-α, hs-CRP, and neutrophil-lymphocyte ratio (NLR)
result TNF-α significantly decreased (Δ5.40 pg/mL, p=0.002); hs-CRP change 0.40 mg/L (p=0.656, NS); NLR difference 0.55 (p=0.055, NS).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested brain damage markers (S-100β, BFABP), Glasgow coma scale, Pediatric Risk of Mortality III, inflammatory cytokines (IL-6, TNF-α), lipid peroxidation (SOD)
result GSH improved brain damage markers (S-100β, BFABP), increased GCS scores, reduced PRISM III scores, lowered IL-6 and TNF-α, and decreased lipid peroxidation in pediatric SAE patients.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GSH/GSSG ratio as diagnostic biomarker for infection type; ROC curve diagnostic accuracy
result Bacterial infections showed higher oxidative stress markers than viral; combined GSH+GSSG analysis with heatmaps and ROC curves improved diagnostic accuracy in distinguishing infection types.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested total effective rate, ALT, AST, GGT, ALB, TNF-α, IL-17, IL-10, adverse reactions
result Total effective rate 94.59% (treatment) vs 76.92% (control, P=.029); ALT/AST significantly lower in treatment group; TNF-α and IL-17 decreased, IL-10 increased (all P=.000).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested association between plasma reduced glutathione and neutrophil / total leukocyte counts
result Reduced glutathione levels significantly associated with neutrophil counts (p=0.009), strongest predictor among variables; clozapine dose and treatment duration also contributed.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested serum alcohol AUC, serum acetaldehyde AUC, hangover symptom questionnaire
result Ready Q: serum alcohol AUC -94.92 mg·h/dL, acetaldehyde AUC -8.441 mg·h/dL vs placebo. Theracurmin alone: alcohol AUC -117.21 mg·h/dL, acetaldehyde AUC -8.161 mg·h/dL.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested salivary glutathione and selenium levels as biomarkers of oral cancer risk
result Glutathione reduced in OSCC (5.047±0.5115 µM) vs high-risk (5.273±0.3240 µM) and low-risk controls (5.618±0.5213 µM); selenium elevated in OSCC and high-risk vs controls.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Whole-blood GSH pharmacokinetics (iAUC0-24, Cmax, Tmax), targeted glutathione-related metabolite panel, clinical safety markers (ALT, AST, ALP, creatinine)
result LMG 300mg vs STD 500mg: iAUC0-24 1287.5 vs 517.8 µg·mL·h (p=0.0064); ΔCmax 103.9 vs 42.8 µg/mL (p=0.0003); ~2.49× higher exposure; dose-normalized ~4×. Safe over 30 days at 600 mg/d.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested glutathione redox homeostasis, antioxidative capacity, nitrosative/carbonyl/oxidative stress, inflammation (IL-12 family, albumin), angiogenesis factors, apoptosis markers
result ccRCC vs. controls: elevated oxidative/electrophile stress, hypoxia, inflammatory and angiogenic factors; reduced anti-inflammatory, antioxidant, and apoptosis markers; glutathione redox altered as active adaptive mechanism.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum S-(PGJ₂)-glutathione level as diagnostic biomarker; AUC, sensitivity, specificity by ROC
result S-(PGJ₂)-glutathione significantly downregulated in DAs; total-cohort AUC=0.949, sensitivity=0.789, specificity=0.949; identified as independent biomarker by multivariate logistic regression.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested OSDI, FACES scale, TFBUT, Schirmer test, NEI fluorescein staining, tear cytokines
result HA + GSH-C4 significantly improved OSDI (p<0.001), FACES (p=0.012), TFBUT (p<0.001), NEI-SS (p<0.001) vs HA alone; 15/16 completed; reversible cytokine elevation noted.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested rat · [Effect of subtherapeutic doses of docetaxel (taxotere) on the efficacy of radiotherapy and pro-oxidant-antioxidant balance in rats with Guerin's carcinoma].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [An experimental study on hepatotoxicity of topiramate in young rats].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Aminothiol receptors for decorporation of intravenously administered (60)Co in the rat.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Antiteratogenic capacity of resveratrol in streptozotocin-induced diabetes in rats].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · A randomized study to assess the efficacy of herbal product to prevent cisplatin-induced nephrotoxicity in a rat model.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Anti-hyperglycaemic Effects of Rutin on Blood Glucose, Oxidative Stress Biomarkers and Lipid Peroxidation in Alloxan-induced Hyperglycaemic Wistar Rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Baicalin treats cerebral ischemia reperfusion-induced brain edema in rats by inhibiting TRPV4 and AQP4 of astrocytes].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Effect of electroacupuncture of "Weizhong" (BL40) on iron metabolism disorder in rats with lumbar multifidus muscle injury].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Antioxidant activity enhancement and oxidative damage inhibition by Lagenaria breviflora fruit and Xanthosoma sagittifolium corm in hypertensive Wistar rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Antioxidant Properties of Novel Lipophilic Fluoroquinolone Compounds Against Oxidative Stress Induced by Acetaminophen and Carbon Tetrachloride in Male Wistar Rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · A multi-target approach using Moringa oleifera leaf extract in ameliorating PTZ-induced epilepsy-like neurobehavior in male rats: in vivo and in silico study.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · AI-2 combined with Lactobacillus rhamnosus GG remodels gut microbiota structure to alleviate intestinal oxidative stress injury in a mouse necrotizing enterocolitis model.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Effects of rapamycin treatment on pancreatic fibrosis, cellular apoptosis and oxidative stress in experimental chronic pancreatitis model.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Carbon-Dot-Based Nanosensors for the Detection of Intracellular Redox State.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Disruption of the methionine cycle and reduced cellular gluthathione levels underlie potex-potyvirus synergism in Nicotiana benthamiana.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Different cellular mechanism of imidacloprid and acetamiprid by a combined targeted lipidomics and metabolomics approach in Neuro-2a cells.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction-Sensitive Nanoparticles at the "Cellular Level" and Synergize PD-1 Blockade Therapy.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Enhanced Biocompatibility by Evaluating the Cytotoxic and Genotoxic Effects of Magnetic Iron Oxide Nanoparticles and Chitosan on Hepatocellular Carcinoma Cells (HCC).
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested African swine fever virus enhances viral replication by increasing intracellular reduced glutathione levels, which suppresses stress granule formation.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Glutathione Impacts Both Batrachochytrium dendrobatidis Virulence and Amphibian Cellular Defense in a Chytridiomycosis Model.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested 5-oxoproline supplementation enhances maturation and developmental competence of low-quality porcine cumulus-oocyte complexes during in vitro maturation.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Comparative Evaluation of Plumbagin and Sorafenib in NDEA-TAA-Induced Hepatocellular Carcinoma: Effects on Hepatic Function, Redox Homeostasis and Histopathology.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Evaluation the role of quinoa seeds in attenuation the brain cellular senescence and aging induced by D-galactose and γ-radiation in rats: insights into autophagy, telomerase activity, amyloid-β and tau proteins.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.